Superiority of Neoadjuvant Chemotherapy Over Neoadjuvant Chemoradiotherapy in Esophageal Cancer

Neoadjuvant chemotherapy demonstrates better long-term survival outcomes compared to neoadjuvant chemoradiotherapy. Although the latter may exhibit a higher pathological complete response rate, it does not necessarily translate to improved survival. Additionally, neoadjuvant chemoradiotherapy is associated with higher 30-day mortality and unclear postoperative complications, potentially compromising patients’ quality of life.